A new experimental vaccine takes aim at one of tuberculosis’s most stubborn defenses: the ability of bacteria to persist despite treatment. In a study published in the Journal of Clinical Investigation, researchers from Johns Hopkins Medicine and the Johns Hopkins…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.